Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01029444 · ClinicalTrials.gov registry record · Phase 3
Effects of Pulsed Intravenous (IV) Insulin on Brittle and Uncontrolled Diabetes
A Phase 3 study, sponsored by Florida Atlantic University.
- Terminated
- Registry status
- Phase 3
- Development phase
- 300
- Enrollment target
NCT01029444 is a Phase 3 study that was terminated before completion, run by Florida Atlantic University. The registered enrollment target is 300 participants.
The verdict
NCT01029444, a Phase 3 study, was terminated before completion, sponsored by Florida Atlantic University.
- TERMINATED
- Registry status
- Phase 3
- Development phase
- 300 participants
- Enrollment target
Study Summary
The purpose of this study is to determine if restoring normal metabolic function in patients with either type I or type II diabetes can improve the impact of the consequences of diabetic complications specifically on the wide swings in blood glucoses with erratic control even under optimal conditions. Patients are treated once a week with pulsatile intravenous insulin therapy mimicking normal insulin secretion. Blood sugar diaries and laboratory tests including quarterly Hemoglobin A1c levels are monitored to measure progress and outcomes.
Interventions
- PROCEDURE Pulsatile Intravenous Insulin Therapy (Humulin, Humulog, Novolog )
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 300 participants |
| Start Date | 2007-03 |
| Est. Completion | 2012-03 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01029444
The ClinicalTrials.gov registry entry for NCT01029444 describes a study currently listed as terminated, categorized as Phase 3. The registered enrollment target is 300 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Florida Atlantic University, which has 27 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Pulsatile Intravenous Insulin Therapy (Humulin, Humulog, Novolog ) is the first listed.
NCT01029444 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01029444 about?
NCT01029444 is a clinical study titled "Effects of Pulsed Intravenous (IV) Insulin on Brittle and Uncontrolled Diabetes". The purpose of this study is to determine if restoring normal metabolic function in patients with either type I or type II diabetes can improve the impact of the consequences of diabetic complications specifically on the wide swings in blood glucoses with erratic control even under optimal condition...
What is the current status of trial NCT01029444?
This trial is currently terminated. It is a Phase 3 study. The enrollment target is 300 participants. The study started on 2007-03. Estimated completion is 2012-03.
What interventions are being tested in trial NCT01029444?
The interventions under investigation include: Pulsatile Intravenous Insulin Therapy (Humulin, Humulog, Novolog ) (PROCEDURE).
Who is sponsoring clinical trial NCT01029444?
This trial is sponsored by Florida Atlantic University, which has 27 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.